REMEGEN CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.5 HKD | +0.83% |
|
+10.11% | -18.56% |
| 26/04 | RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04/04 | Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication | MT |
| Sales 2024 * | 1.69B 233M 1.83B 19.45B | Sales 2025 * | 2.49B 343M 2.69B 28.64B | Capitalization | 25.2B 3.48B 27.23B 290B |
|---|---|---|---|---|---|
| Net income 2024 * | -1.15B -158M -1.24B -13.21B | Net income 2025 * | -688M -94.95M -743M -7.92B | EV / Sales 2024 * | 15.5 x |
| Net Debt 2024 * | 1.01B 139M 1.09B 11.58B | Net Debt 2025 * | 1.82B 251M 1.96B 20.9B | EV / Sales 2025 * | 10.9 x |
| P/E ratio 2024 * |
-13.4
x | P/E ratio 2025 * |
-22.5
x | Employees | 3,615 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.32% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.83% | ||
| 1 week | +10.11% | ||
| Current month | +12.34% | ||
| 1 month | +18.91% | ||
| 3 months | +57.70% | ||
| 6 months | -26.33% | ||
| Current year | -18.56% |
1 week
27.25
31.80
1 month
24.8034.45
Current year
14.9637.45
1 year
14.9650.30
3 years
14.96145.50
5 years
14.96149.80
10 years
14.96149.80
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Min Fang
CEO | Chief Executive Officer | 62 | 04/08/04 |
Shao Jing Tong
DFI | Director of Finance/CFO | 53 | 28/23/28 |
Ruyi He
CTO | Chief Tech/Sci/R&D Officer | 63 | 11/20/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xian Jing Hao
BRD | Director/Board Member | 59 | 11/20/11 |
Yun Jin Chen
BRD | Director/Board Member | 39 | 05/22/05 |
Jian Min Fang
CEO | Chief Executive Officer | 62 | 04/08/04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.27% | 4 M€ | -27.92% | ||
| 0.12% | 2 M€ | -14.14% | ||
| 0.00% | 7 M€ | +1.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 30.5 | +0.83% | 1,169,158 |
| 25/24/25 | 30.25 | +2.89% | 1,931,164 |
| 24/24/24 | 29.4 | -2.00% | 801,796 |
| 23/24/23 | 30 | +5.82% | 2,057,000 |
| 22/24/22 | 28.35 | +2.35% | 450,534 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 01:38 pm IST
More quotes
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.
Calendar
20/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
28.23
CNY
Average target price
39.93
CNY
Spread / Average Target
+41.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.56% | 3.48B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 9995 Stock
